FLII
protein-codingFLII actin remodeling protein, the group of Gelsolin/villins
Gene summary
This gene encodes a protein with a gelsolin-like actin binding domain and an N-terminal leucine-rich repeat-protein protein interaction domain. The protein is similar to a Drosophila protein involved in early embryogenesis and the structural organization of indirect flight muscle. The gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~13.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0957984
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0957984
Submitter: ClinGen
FLII was evaluated for autosomal recessive dilated cardiomyopathy (DCM). In addition to DCM, FLII has also been reported as a possible candidate gene for Smith Magenis Syndrome at the time of review. This was considered in accordance with ClinGen lumping and splitting criteria. Due to distinct differences in disease mechanism, inheritance, and phenotype, the curation was split and curated for autosomal recessive, isolated idiopathic DCM. Human genetic evidence supporting this gene-disease relationship includes case-level data. At least four variants (nonsense, missense) have been reported in humans with DCM. A total of three cases from three independent families were reviewed from two primary publications. Two probands were from consanguineous families (Al-Hassnan et al. 2020 PMID: 32870709). These probands were homozygous for rare, missense FLII variants identified via whole exome sequencing after prioritizing analysis for variants in comprehensive list of 146 well-established cardiomyopathy associated genes was elusive. The third case was a proband from a non-consanguineous Dutch family (Ruijmbeek et al. 2023 PMID 37561591) who was identified to be compound heterozygous for a rare nonsense and rare missense variant in FLII with sequencing of parents confirming variants were in trans. In addition, this gene-disease assertion is supported by expression data, mice and zebrafish animal models, and functional data. Following identification of human FLII from the Drosophila melanogaster homolog by Campbell et al. 1993, Northern blot analysis of various human tissues identified the second highest expression in cardiac tissue (Campbell et al., 1997 PMID: 9177775). Given germline homozygous FLII deletion is embryonically lethal in mice, a cardiac-specific knock-out (KO) was created postnatally with aMHC-Cre mediated expression with LoxP sites targeting exons 8 to 14 of FLII (Kuwabara et al. PMID: 37126682). Phenotypic analysis via echocardiograms at 16 weeks revealed significant increase in left ventricular body weight ratio and significant decrease in fractional shortening in cardiac-specific mutant mice versus aMHC-Cre controls. Additional phenotypic analysis of tamoxifen-induced cardiac specific Cre-mediated FLII KO (induced at 4 weeks) was completed in pre- and post-stress state. Echocardiographic findings at 11 weeks following 3 weeks of transverse aortic constriction stress recapitulated a DCM-concerning phenotype, supporting importance of FLII function in cardiac homeostasis (Kuwabara et al. PMID: 37126682). In zebrafish, Ruijmbeek et al., 2023 created compound heterozygous and homozygous zebrafish progeny corresponding to previously detailed human variants via CRISPR-CAS9 methodology. High-speed imaging technology at 120 hours post fertilization (hpf) identified significantly reduced ventricular contractility and ejection fraction in zebrafish mutants compared to controls (Ruijmbeek et al., 2023 PMID: 37561591). A variety of additional experiments in mutant mice and zebrafish support FLII function in cell adhesion complexes and myocardium organization. In HEK293T cells, co-immunoprecipitant analysis with overexpression of FLAG-tagged FLII followed by mass spectrometry identified actin as one of the interacting substrates (Kuwabara et al. 2023 PMID: 37126682). Confocal microscopy of isolated cardiomyocytes from mutant mice at 16 weeks of age compared to controls revealed abnormal shortening in the thin filament, while electron microscopy of KO mutant heart tissue at 6 months revealed disturbed organization of the intercalculated discs and sarcomere dysgenesis (Kuwabara et al., 2023 PMID: 37126682). In homozygous missense and truncating zebrafish compared to controls, confocal and transmission electron microscopy imaging at 120 hpf revealed disorganized, primitive cardiac trabeculae with irregular filament organization, myofibril orientation and maturation. Furthermore, localization studies for cell-adhesion proteins vinculin and cadherin2 through 3D confocal projections and quantitative pixel intensity plots at 60 hpf in isolated cardiomyocytes of homozygous truncating mutants compared to controls showed abnormally dispersed localization and reduced intensity (Ruijmbeek et al., 2023 PMID: 37561591). In summary, there is moderate evidence to support this gene-disease relationship. More evidence is needed to establish the relationship of FLII with AR DCM definitively. This classification was approved by the ClinGen Dilated Cardiomyopathy Working Group on 6/14/2024 (SOP Version 10).
Inheritance Pattern: AR
Disease ID:MONDO:0957984
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular
Intervention: Cardiovascular
Rationale: Individuals can manifest with severe and early-onset cardiomyopathy, and awareness can allow early diagnosis and management
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to FLII variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_002018.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 23 | 5 | 30 | ||
| missense | 1 | 1 | 227 | 7 | 2 | 238 |
| nonsense | 1 | 2 | 3 | |||
| start loss | 0 | |||||
| frameshift | 1 | 1 | ||||
| splice donor/acceptor (+/-2bp) | 1 | 6 | 7 | |||
| Total | 2 | 3 | 237 | 30 | 7 | 279 |
Highest pathogenic variant AF is 0.000027269436
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_002009.1 | 30 | MANE Select | |
| Ensembl | ENSP00000324573.4 | 30 | MANE Select | |
| RefSeq | NP_001243193.1 | 30 | Standard | |
| RefSeq | NP_001243194.1 | 29 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| flii | Danio rerio | Structure: fast muscle cell Quality: disorganized abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- multicellular organism development
- actin cytoskeleton organization
- actin filament severing
Molecular Function
- actin binding
- protein binding
- actin filament binding
Cellular Component
- nucleoplasm
- microtubule organizing center
- cytosol
- brush border
- focal adhesion
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000327031
- Coding exons
- 30
- Length
- 14081
- Individuals with no LoFs
- 125633
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 115
- Defined
- 125748
- p
- 0.000457
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.507 | 753 | 793 | 0.949 | 0.0000527 | 8321 |
| Missense (PolyPhen) | 242 | 280.75 | 0.86199 | 2922 | ||
| Synonymous | -1.97 | 379 | 333 | 1.14 | 0.0000224 | 2439 |
| Loss of Function | 4.23 | 31 | 68.9 | 0.450 | 0.00000352 | 757 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00018 | 0.00018 | rare |
| Latino/Admixed American | 0.00049 | 0.00049 | rare |
| Ashkenazi Jewish | 0.00010 | 0.000099 | rare |
| East Asian | 0.000054 | 0.000054 | rare |
| Finnish | 0.000092 | 0.000092 | rare |
| European (Non-Finnish) | 0.00033 | 0.00033 | rare |
| South Asian | 0.0017 | 0.0017 | notable |
| Other | 0.00049 | 0.00049 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: May play a role as coactivator in transcriptional activation by hormone-activated nuclear receptors (NR) and acts in cooperation with NCOA2 and CARM1. Involved in estrogen hormone signaling. Involved in early embryonic development (By similarity). May play a role in regulation of cytoskeletal rearrangements involved in cytokinesis and cell migration, by inhibiting Rac1-dependent paxillin phosphorylation. {ECO:0000250, ECO:0000269|PubMed:14966289}.;
Recessive Scores
- pRec
- 0.234
Intolerance Scores
- LoFtool
- 0.779
- RVIS EVS
- -2.94
- RVIS percentile EVS
- 0.55
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- S
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.787
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |